TY - JOUR
T1 - Adolescent Perspectives on the Burden of a Parent's Migraine
T2 - Results from the CaMEO Study
AU - Buse, Dawn C.
AU - Powers, Scott W.
AU - Gelfand, Amy A.
AU - VanderPluym, Juliana H.
AU - Fanning, Kristina M.
AU - Reed, Michael L.
AU - Adams, Aubrey Manack
AU - Lipton, Richard B.
N1 - Funding Information:
Richard B. Lipton, MD, serves on the editorial board of Neurology and as senior advisor to Headache. He has received research support from the NIH. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the NIA and NINDS, serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Colucid, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Novartis, Teva, and Vedanta. He receives royalties from Wolff’s Headache, 8th Edition, Oxford Press University, 2009, and Informa. He holds stock options in eNeura Therapeutics and Biohaven.
Funding Information:
Amy A. Gelfand, MD, has received research grant support from eNeura, Allergan, and EMKinetics. She has consulted for Biohaven, Eli Lilly, and Zosano, and has received travel expenses from Teva. Her spouse has received research support from Gen-entech, Quest Diagnostics, and MedDay, and consulting fees from Genentech. Juliana H. VanderPluym, MD, has consulted for Novartis.
Funding Information:
Financial Disclosures and Conflicts of Interest: Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Amgen, Avanir, Dr. Reddy’s Laboratories, Eli Lilly, MAP Pharmaceuticals, Novartis, and Zogenix. She is an employee of Mon-tefiore Medical Center, which has received research support from Allergan, Alder, Avanir, CoLucid, Dr. Reddy’s Laboratories, Endo Pharmaceuticals, GlaxoSmithKline, Labrys, MAP Pharmaceuticals, Merck, NuPathe, Novartis, Ortho-McNeil, and Zogenix, via grants to the National Headache Foundation and/or Montefiore Medical Center. She is on the editorial board of Current Pain and Headache Reports, the Journal of Headache and Pain, Pain Medicine News, and Pain Pathways magazine.
Publisher Copyright:
© 2018 American Headache Society
PY - 2018/4
Y1 - 2018/4
N2 - Objective: To assess the impact of parental migraine on adolescents (aged 13-21 years) living within the parental home from the adolescent's perspective. Background: Family members are affected by their parent's migraine. We surveyed adolescents on the social, academic, and emotional effects of their parent's migraine. Methods: The Chronic Migraine Epidemiology and Outcomes (CaMEO) study was a longitudinal Web-based study with cross-sectional modules designed to assess migraine symptoms, severity, frequency, and disability; migraine-related consulting practices, healthcare utilization, medication use, comorbid health conditions, and family related burden associated with migraine. The Family Burden Module (adolescent version; FBM-A) from the CaMEO study assessed parents with migraine and adolescent household members (dyads). Adolescents ranged in age from 13-21 years and were living at home with their parent. The initial FBM-A survey included 52 items covering five domains, which was refined and reduced by confirmatory factor analysis to 36 items covering four domains. Depression (9-item Patient Health Questionnaire) and anxiety (7-item Generalized Anxiety Disorder scale) were assessed. Item responses were stratified by parent migraine status (episodic migraine [EM], <15 headache days/month; chronic migraine [CM], ≥15 headache days/month). Frequencies of activities/events missed because of parental headache were categorized as ≥1 time or ≥4 times/previous 30 days. Results: The sample included 1,411 parent-adolescent dyads (parent with EM, n = 1,243 [88.1%]; parent with CM, n = 168 [11.9%]). Burden due to a parent's migraine was reported in four domains based on 36 items including: Loss of Parental Support and Reverse Caregiving (5 items); Emotional Experience (13 items); Interference with School (4 items); and Missed Activities and Events (14 items). Across domains, perceived burden was greater for adolescents of parents with CM vs EM. Rates of moderate-to-severe anxiety symptoms were higher among adolescents of parents with CM (6.2 vs 11.3%, P =.01), while moderate-to-severe depression symptom rates were similar (5.5 vs 8.9%, P =.08). More adolescents of CM vs EM parents reported having a headache within the previous 3 months (P <.001). Conclusions: Parental migraine negatively impacts adolescent children, extending our understanding of the family burden of migraine and emphasizing the potential benefit to children of optimizing migraine care.
AB - Objective: To assess the impact of parental migraine on adolescents (aged 13-21 years) living within the parental home from the adolescent's perspective. Background: Family members are affected by their parent's migraine. We surveyed adolescents on the social, academic, and emotional effects of their parent's migraine. Methods: The Chronic Migraine Epidemiology and Outcomes (CaMEO) study was a longitudinal Web-based study with cross-sectional modules designed to assess migraine symptoms, severity, frequency, and disability; migraine-related consulting practices, healthcare utilization, medication use, comorbid health conditions, and family related burden associated with migraine. The Family Burden Module (adolescent version; FBM-A) from the CaMEO study assessed parents with migraine and adolescent household members (dyads). Adolescents ranged in age from 13-21 years and were living at home with their parent. The initial FBM-A survey included 52 items covering five domains, which was refined and reduced by confirmatory factor analysis to 36 items covering four domains. Depression (9-item Patient Health Questionnaire) and anxiety (7-item Generalized Anxiety Disorder scale) were assessed. Item responses were stratified by parent migraine status (episodic migraine [EM], <15 headache days/month; chronic migraine [CM], ≥15 headache days/month). Frequencies of activities/events missed because of parental headache were categorized as ≥1 time or ≥4 times/previous 30 days. Results: The sample included 1,411 parent-adolescent dyads (parent with EM, n = 1,243 [88.1%]; parent with CM, n = 168 [11.9%]). Burden due to a parent's migraine was reported in four domains based on 36 items including: Loss of Parental Support and Reverse Caregiving (5 items); Emotional Experience (13 items); Interference with School (4 items); and Missed Activities and Events (14 items). Across domains, perceived burden was greater for adolescents of parents with CM vs EM. Rates of moderate-to-severe anxiety symptoms were higher among adolescents of parents with CM (6.2 vs 11.3%, P =.01), while moderate-to-severe depression symptom rates were similar (5.5 vs 8.9%, P =.08). More adolescents of CM vs EM parents reported having a headache within the previous 3 months (P <.001). Conclusions: Parental migraine negatively impacts adolescent children, extending our understanding of the family burden of migraine and emphasizing the potential benefit to children of optimizing migraine care.
KW - adolescent
KW - burden of illness
KW - family
KW - migraine
UR - http://www.scopus.com/inward/record.url?scp=85044933388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044933388&partnerID=8YFLogxK
U2 - 10.1111/head.13254
DO - 10.1111/head.13254
M3 - Article
C2 - 29355924
AN - SCOPUS:85044933388
SN - 0017-8748
VL - 58
SP - 512
EP - 524
JO - Headache
JF - Headache
IS - 4
ER -